S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

Authors: Francesco Passamonti, Andrea Patriarca, Steven Knapper, Candido Rivera, Joseph M Scandura, Timothy Devos, Nikki Granacher, Adam Mead, Stephen Oh, Jeanne Palmer, Raajit K Rampal, Lino Teichmann, Qing LI, Jean-Pierre Eliane, Tzuu-Wang Chang, Sandra Klein, Gozde Colak, Claire Harrison

Source: HemaSphere, Vol 7, p e9927843 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000967584.99278.43; https://doaj.org/toc/2572-9241

Access URL: https://doaj.org/article/7ddf83147e984511807a01aa1e288684

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Authors: Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat

Source: Hematology, Vol 27, Iss 1, Pp 23-31 (2022)

Subject Terms: ruxolitinib, myelofibrosis, symptom burden, splenomegaly, transplantation, anemia, reimbursement, belgium, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/1607-8454

Access URL: https://doaj.org/article/4ce47c4650ca4f16a5e8051669428d06

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Authors: Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E, Saikia, Tapan, Charbonnier, Aude ^*, Apperley, Jane F., Rathnam, Krishna ^*, Deininger, Michael W., De Lavallade, Hugues ^*, Khattry, Navin ^*, Whiteley, Andrew, Mauro, Michael J., Verhoef, Gregor ^*, Gambacorti-Passerini, Carlo, Lucchesi, Alessandro ^*, Apte, Shashikant, Nikki, Granacher ^*, Yao, Siu-Long, Kothekar, Mudgal ^*, Sreenivasan, Jayasree ^*, HV, Bimba ^*, Chimote, Geetanjali ^*

Source: In Blood 13 November 2019 134 Supplement 1:4158-4158

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing = 3 Prior TKI Therapies: Initial Safety and Efficacy

Authors: Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E, Saikia, Tapan, Charbonnier, Aude, Apperley, Jane F., Rathnam, Krishna, Deininger, Michael W., De Lavallade, Hugues, Khattry, Navin, Whiteley, Andrew, Mauro, Michael J., Verhoef, Gregor, Gambacorti-Passerini, Carlo, Lucchesi, Alessandro, Apte, Shashikant, Nikki, Granacher, Yao, Siu-Long, Kothekar, Mudgal, Sreenivasan, Jayasree, HV, Bimba, Chimote, Geetanjali

Source: Blood; November 2019, Vol. 134 Issue: Supplement 1 p4158-4158, 1p